目的:本研究旨在评估Forskolin和二甲双胍(单独和联合使用)对葡萄糖的协同作用,血液学,肝脏血清,和糖尿病患者的氧化应激参数,健康,和肝细胞癌(HCC)诱导的大鼠。
方法:雄性Wistar大鼠80只,随机分为10个实验组(每组8只),包括1)健康组,2)糖尿病组,3)HCC组,4)糖尿病+二甲双胍(300mg/kg),5)糖尿病+毛喉素(100毫克/千克),6)糖尿病+二甲双胍(300毫克/千克)和Forskolin(100毫克/千克),7)肝癌+二甲双胍(300毫克/千克),8)肝癌+毛喉素(100毫克/千克),9)肝癌+二甲双胍(300毫克/千克)和Forskolin(100毫克/千克),和10)健康组+二甲双胍(300mg/kg)和Forskolin(100mg/kg)。每天给大鼠施用Forskolin/二甲双胍,持续8周。葡萄糖,血液学,测量并比较各组之间的肝脏血清参数。丙二醛(MDA)的水平,以及超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)的活性,以及8-羟基脱氧鸟苷(8OHdG)水平,也被测量了。
结果:Forskolin可降低糖尿病大鼠的平均血糖,二甲双胍,Forskolin+二甲双胍治疗占43.5%,47.1%,和53.9%,分别。治疗后HCC大鼠的这些降低值为21.0%,16.2%,和23.7%,分别。对于所有用Forskolin/二甲双胍治疗的糖尿病和HCC大鼠,MDA,SOD,与糖尿病组和肝癌组相比,GPx水平显着改善(P<0.05)。尽管与Forskolin组相比,使用Forskolin二甲双胍治疗的大鼠血液和尿液样本的氧化应激降低更高,在所有参数方面,该组与接受二甲双胍治疗的大鼠之间的差异均不显著.
结论:二甲双胍和Forskolin可降低糖尿病和肝癌大鼠的氧化应激。结果表明,药物组合(二甲双胍和Forskolin)在降低糖尿病大鼠的葡萄糖水平方面比单独的Forskolin具有更大的治疗作用。然而,二甲双胍和Forskolin联合使用对血液和尿液氧化应激的改善作用在统计学上不高于单独使用二甲双胍。
OBJECTIVE: This
study proposed to assess the synergistic effects of Forskolin and Metformin (alone and in combination) on glucose, hematological, liver serum, and oxidative stress parameters in diabetic, healthy, and hepatocellular carcinoma (HCC) induced rats.
METHODS: Eighty male Wistar rats were divided into 10 experimental groups (8 rats for each group), including 1) healthy group, 2) diabetic group, 3) HCC group, 4) diabet + Metformin (300 mg/kg), 5) diabet + Forskolin (100 mg/kg), 6) diabet + Metformin (300 mg/kg) & Forskolin (100 mg/kg), 7) HCC + Metformin (300 mg/kg), 8) HCC + Forskolin (100 mg/kg), 9) HCC + Metformin (300 mg/kg) & Forskolin (100 mg/kg), and 10) healthy group + Metformin (300 mg/kg) & Forskolin (100 mg/kg). The rats were administrated Forskolin/Metformin daily for 8 weeks. Glucose, hematological, and liver serum parameters were measured and compared among the groups. The levels of malondialdehyde (MDA), and the activities of superoxide dismutase (SOD) and glutathione peroxidase (GPx), as well as 8-hydroxydeoxyguanosine (8 OHdG) levels, were also measured.
RESULTS: The average blood glucose reduction in diabetic rats with the Forskolin, Metformin, and Forskolin + Metformin treatments was 43.5%, 47.1%, and 53.9%, respectively. These reduction values for HCC rats after the treatments were 21.0%, 16.2%, and 23.7%, respectively. For all the diabetic and HCC rats treated with Forskolin/Metformin, the MDA, SOD, and GPx levels showed significant improvement compared with the diabetic and HCC groups (P < 0.05). Although the rats treated with Forskolin + Metformin experienced a higher reduction in oxidative stress of blood and urine samples compared to the Forskolin group, the differences between this group and rats treated with Metformin were not significant for all parameters.
CONCLUSIONS: Metformin and Forskolin reduced oxidative stress in diabetic and HCC-induced rats. The results indicated that the combination of agents (Metformin & Forskolin) had greater therapeutic effects than Forskolin alone in reducing glucose levels in diabetic rats. However, the ameliorative effects of combining Metformin and Forskolin on blood and urine oxidative stress were not statistically higher than those of Metformin alone.